All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
B-cell maturation antigen (BCMA)-directed immunotherapies for the treatment of relapsed/refractory multiple myeloma (RRMM) are often associated with high response rates compared with standard of care treatments. However, they are often also accompanied by cytokine elevation, which can lead to cytokine release syndrome (CRS). The incidence of CRS associated with BCMA-directed therapies is well established but rarely stratified by modality and administration route.1
Here, we summarize a meta-analysis by Soltantabar et al.1 published in Clinical Pharmacology and Therapeutics on the impact of treatment modality and the route of administration of immunotherapies on the incidence of CRS in RRMM.
Figure 1. CRS rates associated with CAR T-cell and bispecific antibody therapies*
bsAbs, bispecific antibody; CAR, chimeric antigen receptor.
*Data from Soltantabar, et al.1
Table 1. Incidence of CRS by agent and dose level*
Drug |
Dose level |
Any grade CRS, % |
Grade ≥3 CRS, % |
---|---|---|---|
Elranatamab |
12/32/76 mg |
56.3 |
0 |
4/20/76 mg |
64.4 |
0 |
|
44/76 mg; no premed |
100 |
0 |
|
44/76 mg premed |
78.3 |
4.3 |
|
1,000 μg/kg (76 mg) |
100 |
0 |
|
600 μg/kg (44 mg) |
100 |
0 |
|
Linvoseltamab |
5/20/50 mg IV |
54.8 |
1.9 |
5/20/200 mg IV |
45.3 |
0.8 |
|
Alnuctamab |
3/6/10 mg SC |
72 |
0 |
3/6/30 mg SC |
44 |
0 |
|
3/6/10 mg IV |
71 |
2 |
|
ABBV-383 |
40 mg IV |
69 |
0 |
60 mg IV |
70 |
2 |
|
CRS, cytokine release syndrome; IV, intravenous; SC, subcutaneous. |
Key learnings1 |
---|
|
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox